AGN News 142.00 04/21/2014 19:53:37 Allergan Inc (AGN)
Post# of 273249
Posted On: 04/21/2014 8:53:39 PM
Allergan Inc (AGN) 142.00 $AGN
Pershing Square and Valeant's Allergan Deal a Watershed for Activism
at The Street - 43 mins ago
Pershing Square Capital Management may be re-writing the rules of activist investing after teaming up with Valeant Pharmaceuticals on a potential takeover of Allergan.
Roche Launches Kadcyla in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 53 mins ago
Roche's breast cancer franchise received a boost when it announced that it has launched its cancer drug Kadcyla in Japan.
NYSE stocks posting largest percentage increases
AP - 2 hrs 50 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
Stocks Rise; Valeant, Netflix Soar After Hours
at Investor's Business Daily - Mon Apr 21, 4:00PM CDT
Stocks rose Monday, with the S&P 500 notching its fifth straight gain, as quarterly earnings reports continue to roll out. Valeant Pharmaceuticals (VRX) soared in post-session trading after The Wall Street Journal reported that the Canadian drugmaker...
Why Allergan (AGN) Soared After Hoursin After Market Trading Today
at The Street - Mon Apr 21, 3:42PM CDT
Allergan (AGN) soared in after-hours trading on Monday amid news that activist investor William Ackman and Valeant Pharmaceuticals International have joined forces to pursue a takeover of the health care company. Ackman is the founder and CEO of...
SmarTrend Watching for Potential Pullback in Shares of Allergan After 6.03% Gain
Comtex SmarTrend(R) - Mon Apr 21, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $134.10 to a high of $142.00. Yesterday, the shares gained 6.0%, which took the trading range above the 3-day high of $134.41 on volume of 9.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN June 21st Options Begin Trading
at The Street - Mon Apr 21, 10:52AM CDT
Investors in Allergan, Inc saw new options become available today, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGN options chain for the new June 21st contracts and identified one put and...
Next Resistance Level for Allergan (AGN) is $137.72
Comtex SmarTrend(R) - Mon Apr 21, 9:42AM CDT
Shares of Allergan (AMEX:AGN) opened today above their pivot of $132.51 and have already reached the first level of resistance at $135.82. Analysts will be watching for a cross of the next upside pivot targets of $137.72 and $142.93.
Glaxo Looking into Misconduct Charges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:35PM CDT
GlaxoSmithKline recently responded to investigations and charges of misconduct in Jordan and Lebanon.
Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.
Dr. Rian A. Maercks Announces Appointment to Elite ASCENT National Advisory Panel in Plastic Surgery, Comprised of Top 25 Leaders in Innovative Plastic Surgery in the U.S.
PR Newswire - Thu Apr 17, 7:45AM CDT
In recognition of expertise and interest in delivering the most innovative aesthetically superior treatment options, Dr. Rian A. Maercks has been appointed to the elite Allergan ASCENT advisory board of the top 25 leaders in plastic surgery in the U.S.
TauTona Group Sells Aline HA(R) to Allergan
Marketwire - Thu Apr 17, 7:30AM CDT
TauTona Group, a medical device incubator and investment fund focused on the rapid development of innovative medical products, today announced that its wholly-owned subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc. The Aline HA technology is under development for use as a dermal filler.
Stocks On Track For Third Gain; Allergan Rises
at Investor's Business Daily - Wed Apr 16, 1:54PM CDT
Stocks continued to hold near their session highs Wednesday afternoon and had little reaction to the Fed's beige book. The Dow Jones industrial average and the Nasdaq rose 0.8% each, while the S&P 500 climbed 0.7%. All three were on pace for a third...
Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.
Trade-Ideas: Allergan (AGN) Is Today's Momo Momentum Stock
at The Street - Wed Apr 16, 8:46AM CDT
Trade-Ideas LLC identified Allergan (AGN) as a momo momentum candidate
Another Earnings Beat from J&J, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 1:17PM CDT
J&J's earnings streak continues with the company reporting strong first quarter results and raising its guidance for the year.
Top-of-Mind Companies in Facial Injectable and Laser/Energy Device Markets Are Similar in Europe and Asia
PR Newswire - Tue Apr 15, 9:00AM CDT
Decision Resources Group, in collaboration with IMCAS (International Master Course on Aging Skin), finds that the top-of-mind companies in each of the botulinum toxin (BTX), dermal filler and laser/energy device markets are similar in Europe and in Asia. Not surprisingly, Allergan's BOTOX Cosmetic continues to be the top-of-mind BTX brand in both Asia and Europe, with Allergan's JUVEDERM and Galderma's Restylane both having high recognition among dermal filler brands. Lumenis came out on top for laser/energy devices in both regions.
3 Big-Volume Stocks in Breakout Territory
at The Street - Tue Apr 15, 7:23AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Global Retinal Vein Occlusion Therapeutics Pipeline Review 2014 - Analysis of 5 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jr9qs5/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Retinal Vein Occlusion - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV Drug Profiles - fluocinolone acetonide - beclomethasone dipropionate - ranibizumab - ocriplasmin - NCX-434 - NCX-422 For more information visit http://www.researchandmarkets.com/research/jr...tinal_vein
After Yesterday's Rally of 2.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 14, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $120.72 to a high of $124.46. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $121.96 on volume of 7.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Pershing Square and Valeant's Allergan Deal a Watershed for Activism
at The Street - 43 mins ago
Pershing Square Capital Management may be re-writing the rules of activist investing after teaming up with Valeant Pharmaceuticals on a potential takeover of Allergan.
Roche Launches Kadcyla in Japan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - 1 hr 53 mins ago
Roche's breast cancer franchise received a boost when it announced that it has launched its cancer drug Kadcyla in Japan.
NYSE stocks posting largest percentage increases
AP - 2 hrs 50 mins ago
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
Stocks Rise; Valeant, Netflix Soar After Hours
at Investor's Business Daily - Mon Apr 21, 4:00PM CDT
Stocks rose Monday, with the S&P 500 notching its fifth straight gain, as quarterly earnings reports continue to roll out. Valeant Pharmaceuticals (VRX) soared in post-session trading after The Wall Street Journal reported that the Canadian drugmaker...
Why Allergan (AGN) Soared After Hoursin After Market Trading Today
at The Street - Mon Apr 21, 3:42PM CDT
Allergan (AGN) soared in after-hours trading on Monday amid news that activist investor William Ackman and Valeant Pharmaceuticals International have joined forces to pursue a takeover of the health care company. Ackman is the founder and CEO of...
SmarTrend Watching for Potential Pullback in Shares of Allergan After 6.03% Gain
Comtex SmarTrend(R) - Mon Apr 21, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $134.10 to a high of $142.00. Yesterday, the shares gained 6.0%, which took the trading range above the 3-day high of $134.41 on volume of 9.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
AGN June 21st Options Begin Trading
at The Street - Mon Apr 21, 10:52AM CDT
Investors in Allergan, Inc saw new options become available today, for the June 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGN options chain for the new June 21st contracts and identified one put and...
Next Resistance Level for Allergan (AGN) is $137.72
Comtex SmarTrend(R) - Mon Apr 21, 9:42AM CDT
Shares of Allergan (AMEX:AGN) opened today above their pivot of $132.51 and have already reached the first level of resistance at $135.82. Analysts will be watching for a cross of the next upside pivot targets of $137.72 and $142.93.
Glaxo Looking into Misconduct Charges - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 5:35PM CDT
GlaxoSmithKline recently responded to investigations and charges of misconduct in Jordan and Lebanon.
Roche Meets Sales Estimates in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 3:00PM CDT
Sales of $13.0 billion were in line with the Zacks Consensus Estimate in the first quarter.
Dr. Rian A. Maercks Announces Appointment to Elite ASCENT National Advisory Panel in Plastic Surgery, Comprised of Top 25 Leaders in Innovative Plastic Surgery in the U.S.
PR Newswire - Thu Apr 17, 7:45AM CDT
In recognition of expertise and interest in delivering the most innovative aesthetically superior treatment options, Dr. Rian A. Maercks has been appointed to the elite Allergan ASCENT advisory board of the top 25 leaders in plastic surgery in the U.S.
TauTona Group Sells Aline HA(R) to Allergan
Marketwire - Thu Apr 17, 7:30AM CDT
TauTona Group, a medical device incubator and investment fund focused on the rapid development of innovative medical products, today announced that its wholly-owned subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc. The Aline HA technology is under development for use as a dermal filler.
Stocks On Track For Third Gain; Allergan Rises
at Investor's Business Daily - Wed Apr 16, 1:54PM CDT
Stocks continued to hold near their session highs Wednesday afternoon and had little reaction to the Fed's beige book. The Dow Jones industrial average and the Nasdaq rose 0.8% each, while the S&P 500 climbed 0.7%. All three were on pace for a third...
Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 11:41AM CDT
Abbott Laboratories reported first quarter 2014 earnings of 41 cents per share, above the Zacks Consensus Estimate of 35 cents.
Trade-Ideas: Allergan (AGN) Is Today's Momo Momentum Stock
at The Street - Wed Apr 16, 8:46AM CDT
Trade-Ideas LLC identified Allergan (AGN) as a momo momentum candidate
Another Earnings Beat from J&J, View Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 1:17PM CDT
J&J's earnings streak continues with the company reporting strong first quarter results and raising its guidance for the year.
Top-of-Mind Companies in Facial Injectable and Laser/Energy Device Markets Are Similar in Europe and Asia
PR Newswire - Tue Apr 15, 9:00AM CDT
Decision Resources Group, in collaboration with IMCAS (International Master Course on Aging Skin), finds that the top-of-mind companies in each of the botulinum toxin (BTX), dermal filler and laser/energy device markets are similar in Europe and in Asia. Not surprisingly, Allergan's BOTOX Cosmetic continues to be the top-of-mind BTX brand in both Asia and Europe, with Allergan's JUVEDERM and Galderma's Restylane both having high recognition among dermal filler brands. Lumenis came out on top for laser/energy devices in both regions.
3 Big-Volume Stocks in Breakout Territory
at The Street - Tue Apr 15, 7:23AM CDT
These stocks rising on unusual volume are within range of triggering breakout trades.
Global Retinal Vein Occlusion Therapeutics Pipeline Review 2014 - Analysis of 5 Companies and 6 Drug Profiles
M2 - Tue Apr 15, 6:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jr9qs5/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Retinal Vein Occlusion and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Retinal Vein Occlusion products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Retinal Vein Occlusion pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Retinal Vein Occlusion - Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Allergan, Inc. - pSivida Corp. - NicOx S.A. - ThromboGenics NV Drug Profiles - fluocinolone acetonide - beclomethasone dipropionate - ranibizumab - ocriplasmin - NCX-434 - NCX-422 For more information visit http://www.researchandmarkets.com/research/jr...tinal_vein
After Yesterday's Rally of 2.55% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Mon Apr 14, 3:40PM CDT
Allergan (AMEX:AGN) traded in a range yesterday that spanned from a low of $120.72 to a high of $124.46. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $121.96 on volume of 7.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
(0)
(0)Scroll down for more posts ▼